Browsing by Author "Emir, Suna"

Now showing 1 - 3 of 3

Autologous Peripheral Blood Stem Cell Mobilization and Apheresis in Pediatric Patients With Cancer: a Single-Center Report of 64 Procedures
(Wiley, 2024) Erdem, Arzu Yazal; Ozyoruk, Derya; Bozkaya, Ikbal Ok; Cakmakci, Selma; Emir, Suna; Demir, Haci Ahmet; Ozbek, Namik Yasar
Background The published experience concerning autologous peripheral blood stem cell collection in children is very limited. Methods The data of pediatric patients who underwent autologous stem cell mobilization and apheresis between January 2011 and April 2020 were analyzed retrospectively. Results We studied retrospectively 64 mobilization and apheresis procedures in 48 pediatric patients (34 males, 14 females), mean age of 7.31 +/- 5.38 (range, 1.5-19.7) years, the underlying disease was mostly neuroblastoma (NBL). The body weight of 21 patients (43.75%) was 15 kg or less. The targeted autologous peripheral stem cell apheresis (APSCA) was successfully achieved in 98% of patients. Neuroblastoma patients were younger than the rest of the patients and underwent apheresis after receiving fewer chemotherapy cycles than others and all of them mobilized within the first session successfully. Plerixafor was added to mobilization in nine heavily pretreated patients (18.7%), median two doses (range, 1-4 doses). 11 patients (22.9%) underwent radiotherapy (RT) before mobilization with doses of median 24 Gy (range, 10.8-54.0 Gy). Patients with RT were older at the time of apheresis and had received more chemotherapy courses than patients without RT. As a result, patients with a history of RT had significantly lower peripheral CD34+ cells and CD34+ yields than those without RT. In 17 patients (35.4%), 22 different complications were noted. The most common complications were catheter-related infections (n:10, 20.8%), followed by catheter-related thrombosis in eight patients (16.7%). Conclusions Patients who had far less therapy before apheresis were more likely to mobilize successfully. Our study provides a detailed practice approach including complications during APSCA aiming to increase the success rates of apheresis in transplantation centers.
Citation - WoS: 2
Çocukluk Çağı Kanser Yaşayanlarında Nefrotoksisitenin İncelenmesi ve Glomerüler Filtrasyon Hızı Yöntemlerinin Karşılaştırılması
(Dr Behcet Uz Cocuk Hastaliklari ve Cerrahisi, 2021) Erdem, Arzu Yazal; Emir, Suna; Çakar, Nilgün; Demir, Ahmet; Özyörük, Derya
Amaç: Çocukluk çağı kanserlerinde artan sağkalım oranları, uzun süreli tedaviye bağlı yan etkilere ve geç nefrotoksisite için olası risk faktörlerine odaklanmaya yol açmıştır. Amacımız kanser tedavisi alıp iyileşen çocuklarda nefrotoksisiteyi belirlemek ve glomerül filtrasyon hızının hesaplanmasında tahmini glomeruler filtrasyon hızı ile kreatinin klirensinin birbiri ile uyumunu araştırmaktır. Yöntem: Sisplatin, karboplatin, ifosfamid ve/veya yüksek doz metotreksat ile kanser tedavileri tamamlanmış 59 çocuğun glomerüler ve tübüler disfonksiyonları değerlendirildi. Bulgular: Ortalama tanı yaşı 10,7±5,5 yıl (2,5-23), ortalama takip süresi 2,6±2,1 yıl (0,5-8) olan 59 hastanın %65’inde böbrek fonksiyon bozukluğu tespit edildi. Böbrek fonksiyon bozukluğunun en yaygın bulgusu azalmış glomeruler filtrasyon hızı (n:19, %32,2), artmış üriner β2-mikroglobulin atılımı (n:12, %20,4), ardından mikroalbuminuri (n:6, %10,1) idi. Kombine kemoterapi ile tedavi edilenlerde, yüksek doz metotreksat ile tedavi edilenlere göre istatistiksel anlamlı düşük tubüler fosfor reabsorbsiyonu saptandı. Serum sistatin-C ve Schwarz formülü ile hesaplanan tahmini glomeruler filtrasyon hızının birbiri ile tutarlı olduğu (r=0,563, p=0,00) bulundu. Sonuç: Çocukluk çağında kanser tedavisi alıp iyileşenlerde yüksek oranda böbrek komplikasyonlarının geliştiği gösterilmiştir. Çocukluk çağı kanser yaşayanlarında, Schwartz formülü veya sistatin-C ile tahmini glomerüler filtrasyon hızının hesaplanmasının kreatinin klirensiyle uyumlu olduğunu gösterdik. 24 saatlik idrar toplayamayan çocuklarda tahmini glomeruler filtrasyon hızı hesaplaması pratik bir yaklaşımdır.
Citation - WoS: 1
Citation - Scopus: 2
Role of Surveillance Screening in Detecting Tumor Recurrence After Treatment of Childhood Cancers
(Aves, 2021) Kısa, Pelin Teke; Emir, Suna
Objective: As the survival rates in children with cancer reach up to 80%, this improvement in survival increases the number of patients under follow-up. After cancer treatment is completed, patients are taken to follow-up surveillance to ensure the early detection of recurrence and the late effects of treatments. The frequency and necessity of surveillance screening tests are controversial. This study aimed to assess the efficacy of surveillance screening in the detection of recurrence. Material and methods: The files of 533 children who were diagnosed as having cancer at our pediatric oncology clinic between 2004 and 2013 were retrospectively evaluated. We looked at outcomes after recurrence, the timing and pattern of recurrence, the presence of symptoms during recurrence, physical examination findings, tumor marker levels, laboratory findings, and radiologic tests. Results: Of the 63 patients with recurrence, 23 were symptomatic and 40 were asymptomatic at the time of the recurrence. Tumor location and time of the recurrence did not affect the post recurrence survival. The median post-recurrence survival for patients was 13 (range, 1-98) months. The median post-relapse survival was 10 (range, 1-73) months in patients with symp-tomatic recurrence, and 16 (range, 1-98) months in patients with asymptomatic recurrence. It was determined that patients in whom recurrence was identified with surveillance tests had longer post-relapse survival time. The 5-year survival rate of 23 patients with symptomatic recurrence was 12.2%; this rate was 49.5% in asymptomatic patients (p<0.05).Conclusions: It should be considered that surveillance testing offers the benefit of prolonging post recurrence survival.